The investigational sebum-inhibiting topical DRM01 had positive results in a phase 2b study, which paves the way for phase 3 trials planned for 2017.
GlobalMed has represented medical and aesthetic dermatology brands, including BMT, CoolTouch and Radiancy, since 1996. Omnilux noninvasively treats dermatologic conditions, including acne, fine lines and wrinkles and non-melanoma skin cancer.
A growing number of studies suggest diet influences general skin health and specific skin diseases, from acne and eczema to skin aging. Dermatologists share their best practices for using diet to combat skin disease and promote skin health.
While oral isotretinoin has been associated with various side effects and routine blood tests have been recommended, evidence points to inconsistencies in monitoring practices. Many physicians also are questioning whether the effort has value.
Two novel energy-based approaches are ushering in a new era in acne treatment. One expert addresses the role these devices may play.
Experts discuss association between inflammasomes and acne that may lead to treatments stopping acne before clinical signs emerge.
While many are in early phase studies, most of the new topical options are targeting sebum reduction, a novel pathway to controlling acne, and the data are exciting, one expert says.
New findings support dietary and supplementation practices that can influence acne. One expert discusses modifications in context of protocols for managing the condition.
The AAD’s new guidelines for the care and management of acne vulgaris include several updates for dermatologists, including an increased emphasis on oral antibiotic stewardship and recommendations for use.
Allergan announced in late February that the FDA approved its topical Aczone (dapsone) Gel, 7.5% for treatment of acne vulgaris.